欧洲血液学协会(EHA)年会作为全球血液学领域规模最大的国际会议之一,不久前刚刚在意大利米兰落下帷幕。在本次大会上,复星医药发布了自主研发的新型BCL-2抑制剂FCN-338治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(R/R CLL/SLL)的I期研究成果,为进一步探索FCN-338在CLL/SLL的应用提供了重要依据1。BCL-2蛋白是细胞凋亡通路的关键调节因子,在多种恶性血液肿瘤细胞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.